Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NBTX | PRESS-RELEASE | bullish | 7/10 | Nanobiotix announced Part 1 data from the Johnson & Johnson-sponsored Phase 2 CONVERGE study of NBTXR3 (JNJ-1900) in sta | May 17, 2026 |
| REGN | PRESS-RELEASE | bearish | 7/10 | Regeneron announced that its Phase 3 trial of fianlimab (LAG-3 inhibitor) plus cemiplimab in first-line melanoma did not | May 15, 2026 |
| RANI | PRESS-RELEASE | bullish | 5/10 | Rani Therapeutics reported Q1 2026 GAAP EPS of -$0.04, beating consensus of -$0.06 by 33%, with contract revenue rising | May 15, 2026 |
| PSTV | PRESS-RELEASE | bearish | 6/10 | Plus Therapeutics reported Q1 2026 EPS of -$1.05, a 19.2% miss vs consensus of -$0.87, on revenue of $1.0M (grant + CNSi | May 15, 2026 |
| CADL | PRESS-RELEASE | bullish | 8/10 | Candel Therapeutics announced extended follow-up data from the phase 3 trial of aglatimagene (CAN-2409) in localized pro | May 15, 2026 |
| OTLK | PRESS-RELEASE | bearish | 6/10 | Outlook Therapeutics reported Q2 FY2026 results with GAAP net loss of $0.05/share (vs consensus $-0.12) and adjusted net | May 15, 2026 |
| REGN | PRESS-RELEASE | neutral | 2/10 | Regeneron announced the winners of its 2026 International Science and Engineering Fair (ISEF), awarding over $7 million | May 15, 2026 |
| PROK | PRESS-RELEASE | neutral | 5/10 | ProKidney reported Q1 2026 EPS of -$0.14, essentially in line with the -$0.14 consensus (a 1.8% miss), with negligible r | May 15, 2026 |
| QUCY | PRESS-RELEASE | neutral | 2/10 | Quantum Cyber announced the launch of a new corporate website at quantum-cyber.ai, positioning itself as an AI-powered, | May 15, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma reported a Q3 net loss of $6.36M (vs $54.07M in Q3 2025), with zero revenue. The company highlighted a | May 15, 2026 |
| SXTP | PRESS-RELEASE | bearish | 6/10 | Sixty Degrees Pharmaceuticals reported Q1 2026 revenue of $162K (down ~1% YoY) and a net loss of $1.28 per share, signif | May 15, 2026 |
| CMND | PRESS-RELEASE | neutral | 2/10 | Clearmind Medicine's CEO participated in an invite-only federal policy summit at the National Press Club, convened by th | May 15, 2026 |
| MBRX | PRESS-RELEASE | bearish | 6/10 | Moleculin Biotech reported Q1 2026 net loss of $12.8M ($3.54/share) vs $5.9M loss a year ago, with zero revenue. The EPS | May 15, 2026 |
| MENS | PRESS-RELEASE | neutral | 2/10 | Jyong Biotech filed its FY2025 annual report on Form 20-F, a routine regulatory milestone. The press release contains no | May 15, 2026 |
| SLXN | PRESS-RELEASE | bearish | 7/10 | Silexion Therapeutics entered into warrant exercise agreements to raise ~$1M in gross proceeds, issuing new Series C and | May 15, 2026 |
| GALT | PRESS-RELEASE | bullish | 6/10 | Galectin Therapeutics reported Q1 2026 EPS of -$0.08, missing consensus of -$0.06 (-33.3% miss), but highlighted positiv | May 15, 2026 |
| BCDA | PRESS-RELEASE | mixed | 6/10 | BioCardia reported Q1 2026 EPS of -$0.21, missing consensus of -$0.17 by 23.5%, while revenue remained zero. However, th | May 15, 2026 |
| COCP | PRESS-RELEASE | neutral | 5/10 | Cocrystal Pharma reported Q1 2026 EPS of -$0.17, missing consensus of -$0.15 by 13.3%, and recognized $225k in grant rev | May 15, 2026 |
| ATYR | PRESS-RELEASE | neutral | 5/10 | aTyr Pharma reported Q1 2026 EPS of -$0.14, a 3.9% beat vs consensus of -$0.15, on no revenue. The company announced pla | May 15, 2026 |
| CGON | PRESS-RELEASE | bullish | 6/10 | CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, showing 89.5% HG-EFS at | May 15, 2026 |
| IMRX | PRESS-RELEASE | bullish | 7/10 | Immuneering reported Q1 2026 EPS of -$0.21, beating consensus of -$0.25 by 16%, with no revenue. The key catalyst is upc | May 15, 2026 |
| INKT | PRESS-RELEASE | bullish | 6/10 | MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus of -$0.77 by 26%, with net loss narrowing to $2.7M f | May 15, 2026 |
| PVLA | PRESS-RELEASE | bullish | 7/10 | Palvella presented positive Phase 2 TOIVA data at SID showing QTORIN rapamycin statistically significantly reduced bleed | May 15, 2026 |
| ANVS | PRESS-RELEASE | bearish | 6/10 | Annovis Bio reported Q1 2026 EPS of -$0.63, significantly below the -$0.35 consensus estimate, with R&D expenses triplin | May 15, 2026 |
| MSLE | PRESS-RELEASE | neutral | 4/10 | Satellos Bioscience reported a Q1 2026 net loss of $9.8M ($0.53 per share), wider than the $6.1M loss a year ago, driven | May 15, 2026 |
| INDP | PRESS-RELEASE | bearish | 8/10 | Indaptus Therapeutics reported Q1 2026 results with a net loss of $2.5M ($0.23/share), improved from $4.5M ($9.11/share) | May 15, 2026 |
| PPBT | PRESS-RELEASE | neutral | 4/10 | Purple Biotech reported Q1 2026 net loss of $0.1M, significantly narrower than the $0.5M loss in Q1 2025, driven by $2.2 | May 15, 2026 |
| BTAI | PRESS-RELEASE | bearish | 6/10 | BioXcel Therapeutics reported Q1 2026 EPS of -$0.54 (GAAP) vs consensus -$0.48, a -12.5% miss, with IGALMI revenue of $2 | May 15, 2026 |
| TRAW | PRESS-RELEASE | mixed | 5/10 | Traws Pharma reported Q1 2026 results with a net loss of $7.1M (-$0.53 EPS, beating the -$0.56 consensus) and zero reven | May 15, 2026 |
| TIL | PRESS-RELEASE | neutral | 4/10 | Instil Bio reported Q1 2026 GAAP EPS of -$0.62, in line with the consensus estimate of -$0.59 (within the ±2% threshold) | May 15, 2026 |